Cargando…
Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most?
PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conven...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493042/ https://www.ncbi.nlm.nih.gov/pubmed/30708133 http://dx.doi.org/10.1016/j.prro.2019.01.006 |
_version_ | 1783415173958074368 |
---|---|
author | Ntentas, Georgios Dedeckova, Katerina Andrlik, Michal Aznar, Marianne C. George, Ben Kubeš, Jiří Darby, Sarah C. Cutter, David J. |
author_facet | Ntentas, Georgios Dedeckova, Katerina Andrlik, Michal Aznar, Marianne C. George, Ben Kubeš, Jiří Darby, Sarah C. Cutter, David J. |
author_sort | Ntentas, Georgios |
collection | PubMed |
description | PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics. METHODS AND MATERIALS: Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified. RESULTS: Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT. CONCLUSIONS: PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT. |
format | Online Article Text |
id | pubmed-6493042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-64930422019-05-07 Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? Ntentas, Georgios Dedeckova, Katerina Andrlik, Michal Aznar, Marianne C. George, Ben Kubeš, Jiří Darby, Sarah C. Cutter, David J. Pract Radiat Oncol Article PURPOSE: Radiation therapy (RT) improves control of Hodgkin lymphoma (HL), but patients who undergo RT are at risk for late effects, including cardiovascular disease and second cancers, because of radiation doses to organs at risk (OARs). Proton therapy (PT) can reduce OAR doses compared with conventional photon RT. However, access to PT is currently limited, so referrals must be appropriately selective. We aimed to identify subgroups of patients with HL who could benefit the most dosimetrically from RT with PT based on the prechemotherapy disease characteristics. METHODS AND MATERIALS: Normal tissue radiation doses were calculated for 21 patients with HL who were treated with deep-inspiration breath-hold pencil-beam scanning (PBS) PT and compared with doses from 3-dimensional conformal (3D-CRT) and partial arc volumetric modulated (PartArc) photon RT. Prechemotherapy disease characteristics associated with significant dosimetric benefits from PBS compared with photon RT were identified. RESULTS: Treatment with PBS was well tolerated and provided with good local control. PBS provided dosimetric advantages for patients whose clinical treatment volume extended below the seventh thoracic level and for female patients with axillary disease. In addition, an increasing dosimetric benefit for some OARs was observed for increasing target volume. PBS significantly reduced the mean dose to the heart, breast, lungs, spinal cord, and esophagus. Dose homogeneity and conformity within the target volume were also superior with PBS, but some high-dose measures and hot spots were increased with PBS compared with partial arc volumetric modulated photon RT. CONCLUSIONS: PBS gives good target coverage and local control while providing reductions in radiation dose to OARs for individuals who receive RT for HL compared with advanced photon RT. Our findings highlight groups of patients who would be expected to gain more dosimetric benefit from PBS. These findings facilitate the selection of patients who should be considered a priority for PT. Elsevier 2019-05 /pmc/articles/PMC6493042/ /pubmed/30708133 http://dx.doi.org/10.1016/j.prro.2019.01.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ntentas, Georgios Dedeckova, Katerina Andrlik, Michal Aznar, Marianne C. George, Ben Kubeš, Jiří Darby, Sarah C. Cutter, David J. Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title | Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title_full | Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title_fullStr | Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title_full_unstemmed | Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title_short | Clinical Intensity Modulated Proton Therapy for Hodgkin Lymphoma: Which Patients Benefit the Most? |
title_sort | clinical intensity modulated proton therapy for hodgkin lymphoma: which patients benefit the most? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493042/ https://www.ncbi.nlm.nih.gov/pubmed/30708133 http://dx.doi.org/10.1016/j.prro.2019.01.006 |
work_keys_str_mv | AT ntentasgeorgios clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT dedeckovakaterina clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT andrlikmichal clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT aznarmariannec clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT georgeben clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT kubesjiri clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT darbysarahc clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost AT cutterdavidj clinicalintensitymodulatedprotontherapyforhodgkinlymphomawhichpatientsbenefitthemost |